drugset / Trial / NCT00002582

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00002582 ↗

RandomizedTreatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA breast cancer.

Timeline

Start
1993-06
Primary completion
—
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — —
Subject Doxorubicin Other / unclassified — —
Subject Goserelin Other / unclassified — —
Subject Leuprolide Other / unclassified — —
Subject Methotrexate Small molecule — —
Subject fluorouracil Small molecule — —
Background Tamoxifen Small molecule — Oral

Indications